Ibrutinib

Known as: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one, 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)- 
An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-2018
010020030019882018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND MYD88(L265P) and CXCR4(WHIM) mutations are highly prevalent in Waldenström's macroglobulinemia. MYD88(L265P) triggers… (More)
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like (ABC) and germinal center B cell–like (GCB… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing therapeutic target that can… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?